FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3019187839> ?p ?o ?g. }

• W3019187839 abstract "All-trans retinoic acid (ATRA) and arsenic trioxide (ATO) are effective induction therapy for acute promyelocytic leukaemia (APL). However, early thrombo-haemorrhagic complications and mortality remain high. We aimed to investigate how the timing of ATRA initiation and the inclusion of ATO influence patient outcomes. Clinical records were retrospectively reviewed for all patients treated for APL in a single, tertiary centre during 2000-2017. Among 70 patients with APL, 36 (51.4%) presented with thrombo-haemorrhagic complications, and four (5.8%) died within 30 days. The median time to ATRA initiation was 11.2 (range 0-104) h from the time of admission. Patients requiring more transfusions started on ATRA sooner (P = 0.04). Patients with adverse early events did not start ATRA later (P = 0.99). Nevertheless, patients that required additional tests for diagnosis (PML immunofluorescence or molecular) started on ATRA later (28.5 versus 5.3 h; P < 0.0001), and had more thrombo-haemorrhagic complications (P = 0.04). Long-term survival was actually better in patients who started ATRA later (P = 0.03), which is likely explained by higher proportion of low risk patients in this group. Patients treated with ATO (n = 23) maintained higher fibrinogen levels and required less transfusions during induction (P < 0.05), with no disease-related deaths in this group over a median follow-up time of 37.8 months (interquartile range 44.9 months). In summary, fast ATRA initiation reduces early but not late adverse events in APL patients, and the inclusion of ATO helps further improve both early and late outcomes in APL." @default.
• W3019187839 created "2020-05-01" @default.
• W3019187839 creator A5008156063 @default.
• W3019187839 creator A5008216539 @default.
• W3019187839 creator A5017916044 @default.
• W3019187839 creator A5029413117 @default.
• W3019187839 creator A5034402924 @default.
• W3019187839 creator A5050643535 @default.
• W3019187839 creator A5055504996 @default.
• W3019187839 creator A5057402795 @default.
• W3019187839 creator A5066525144 @default.
• W3019187839 creator A5080525489 @default.
• W3019187839 creator A5082961579 @default.
• W3019187839 date "2020-06-01" @default.
• W3019187839 modified "2023-10-03" @default.
• W3019187839 title "Treatment outcomes of patients with acute promyelocytic leukaemia between 2000 and 2017, a retrospective, single centre experience" @default.
• W3019187839 cites W1514735390 @default.
• W3019187839 cites W188837282 @default.
• W3019187839 cites W1976946639 @default.
• W3019187839 cites W1982745688 @default.
• W3019187839 cites W1987176851 @default.
• W3019187839 cites W1993816996 @default.
• W3019187839 cites W1999826261 @default.
• W3019187839 cites W2000380418 @default.
• W3019187839 cites W2008573339 @default.
• W3019187839 cites W2029396015 @default.
• W3019187839 cites W2029456955 @default.
• W3019187839 cites W2032781564 @default.
• W3019187839 cites W2038644330 @default.
• W3019187839 cites W2045926255 @default.
• W3019187839 cites W2046434962 @default.
• W3019187839 cites W2102199763 @default.
• W3019187839 cites W2105404731 @default.
• W3019187839 cites W2129338773 @default.
• W3019187839 cites W2147860795 @default.
• W3019187839 cites W2166981346 @default.
• W3019187839 cites W2174247300 @default.
• W3019187839 cites W2315662514 @default.
• W3019187839 cites W2474389367 @default.
• W3019187839 cites W2559236277 @default.
• W3019187839 cites W2599038384 @default.
• W3019187839 cites W2769006419 @default.
• W3019187839 cites W2801148869 @default.
• W3019187839 cites W2803060244 @default.
• W3019187839 cites W2898470394 @default.
• W3019187839 cites W2918095490 @default.
• W3019187839 cites W2922022567 @default.
• W3019187839 cites W2942720208 @default.
• W3019187839 cites W2965068570 @default.
• W3019187839 cites W2972638668 @default.
• W3019187839 cites W2979569993 @default.
• W3019187839 cites W2991966495 @default.
• W3019187839 cites W570370693 @default.
• W3019187839 doi "https://doi.org/10.1016/j.leukres.2020.106358" @default.
• W3019187839 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32380366" @default.
• W3019187839 hasPublicationYear "2020" @default.
• W3019187839 type Work @default.
• W3019187839 sameAs 3019187839 @default.
• W3019187839 citedByCount "6" @default.
• W3019187839 countsByYear W30191878392020 @default.
• W3019187839 countsByYear W30191878392021 @default.
• W3019187839 countsByYear W30191878392022 @default.
• W3019187839 countsByYear W30191878392023 @default.
• W3019187839 crossrefType "journal-article" @default.
• W3019187839 hasAuthorship W3019187839A5008156063 @default.
• W3019187839 hasAuthorship W3019187839A5008216539 @default.
• W3019187839 hasAuthorship W3019187839A5017916044 @default.
• W3019187839 hasAuthorship W3019187839A5029413117 @default.
• W3019187839 hasAuthorship W3019187839A5034402924 @default.
• W3019187839 hasAuthorship W3019187839A5050643535 @default.
• W3019187839 hasAuthorship W3019187839A5055504996 @default.
• W3019187839 hasAuthorship W3019187839A5057402795 @default.
• W3019187839 hasAuthorship W3019187839A5066525144 @default.
• W3019187839 hasAuthorship W3019187839A5080525489 @default.
• W3019187839 hasAuthorship W3019187839A5082961579 @default.
• W3019187839 hasConcept C104317684 @default.
• W3019187839 hasConcept C119060515 @default.
• W3019187839 hasConcept C126322002 @default.
• W3019187839 hasConcept C141071460 @default.
• W3019187839 hasConcept C167135981 @default.
• W3019187839 hasConcept C185592680 @default.
• W3019187839 hasConcept C190283241 @default.
• W3019187839 hasConcept C197934379 @default.
• W3019187839 hasConcept C2776601000 @default.
• W3019187839 hasConcept C2780386689 @default.
• W3019187839 hasConcept C2781121885 @default.
• W3019187839 hasConcept C55493867 @default.
• W3019187839 hasConcept C71924100 @default.
• W3019187839 hasConcept C90924648 @default.
• W3019187839 hasConceptScore W3019187839C104317684 @default.
• W3019187839 hasConceptScore W3019187839C119060515 @default.
• W3019187839 hasConceptScore W3019187839C126322002 @default.
• W3019187839 hasConceptScore W3019187839C141071460 @default.
• W3019187839 hasConceptScore W3019187839C167135981 @default.
• W3019187839 hasConceptScore W3019187839C185592680 @default.
• W3019187839 hasConceptScore W3019187839C190283241 @default.
• W3019187839 hasConceptScore W3019187839C197934379 @default.
• W3019187839 hasConceptScore W3019187839C2776601000 @default.
• W3019187839 hasConceptScore W3019187839C2780386689 @default.
• W3019187839 hasConceptScore W3019187839C2781121885 @default.

• next